July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Six-month efficacy and safety outcomes of a novel selective EP2 agonist omidenepag isopropyl: the RENGE study (Phase 3)
Author Affiliations & Notes
  • Makoto Aihara
    Ophthalmology, University of Tokyo, Bunkyo-ku, TOKYO, Japan
  • Fenghe Lu
    Santen Inc., Emeryville, California, United States
  • Hisashi Kawata
    Santen Pharmaceutical Co., Ltd., Osaka, Japan
  • Akihiro Iwata
    Santen Pharmaceutical Co., Ltd., Osaka, Japan
  • Noriko Odani-Kawabata
    Santen Pharmaceutical Co., Ltd., Osaka, Japan
  • Naveed K Shams
    Santen Inc., Emeryville, California, United States
    Santen Pharmaceutical Co., Ltd., Osaka, Japan
  • Footnotes
    Commercial Relationships   Makoto Aihara, Santen Pharmaceutical Co., Ltd. (F), Santen Pharmaceutical Co., Ltd. (R); Fenghe Lu, Santen Inc. (E); Hisashi Kawata, Santen Pharmaceutical Co., Ltd. (E); Akihiro Iwata, Santen Pharmaceutical Co., Ltd. (E); Noriko Odani-Kawabata, Santen Pharmaceutical Co., Ltd. (E); Naveed Shams, Santen Inc. (E)
  • Footnotes
    Support  This study was sponsored by Santen.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1229. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Makoto Aihara, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Noriko Odani-Kawabata, Naveed K Shams; Six-month efficacy and safety outcomes of a novel selective EP2 agonist omidenepag isopropyl: the RENGE study (Phase 3). Invest. Ophthalmol. Vis. Sci. 2018;59(9):1229.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Omidenepag isopropyl (OMDI) is a selective EP2 receptor agonist, with a non-prostaglandin structure. This multicenter, open-label, Phase 3 study (NCT02822729) assessed the long-term safety and intraocular pressure (IOP)-lowering efficacy of OMDI 0.002% ophthalmic solution (one drop, once daily) in subjects with open-angle glaucoma (OAG), including normal tension glaucoma, or ocular hypertension (OHT). Here, the 6-month efficacy and safety data are presented.

Methods : Following a 1-4 weeks' washout period, subjects were treated with OMDI 0.002% once daily at 21:00 (±1 hour) for 6 months. Measurements of IOP were performed at 9:00, 13:00, and 17:00 at baseline and at Weeks 2, 4, 8, 12, and 26. Group 1 consisted of subjects with a baseline IOP of ≥16-<22 mmHg, and Group 2 comprised subjects with a baseline IOP of ≥22-<34 mmHg.

Results : Overall, 48 subjects were enrolled in Group 1 and 37 subjects in Group 2. The mean diurnal IOP (±standard deviation) at baseline was 18.7±1.7 mmHg and 24.1±2.4 mmHg in the respective groups. Treatment with OMDI significantly reduced IOP in both groups at each visit (all P<0.0001, compared with baseline). Maximal mean diurnal IOP reduction was reached at Week 2. IOP reduction was sustained during the study (3.5 mmHg at Week 2 to 2.4 mmHg at Week 26 in Group 1; 5.9 mmHg at Week 2 to 4.9 mmHg at Week 26 in Group 2). One patient in Group 2 had a serious adverse event (AE), appendicitis, which was considered unrelated to OMDI; no serious AEs were reported in Group 1. The most frequently reported ocular AEs were conjunctival hyperemia (16/85, 18.8% in Groups 1 and 2 combined), followed by macular edema (ME) including cystoid ME (4/85, 4.7%). Iritis occurred in one patient (1/85, 1.2%). The ME cases were mild or moderate in severity and responsive to standard of care treatment and discontinuation of OMDI; all occurred in pseudophakic eyes. There were no AE reports of increased pigmentation of the iris, eyelid, and eyelashes in either group.

Conclusions : In conclusion, OMDI 0.002% ophthalmic solution demonstrated clinically significant IOP-lowering effects and had an acceptable safety profile in subjects with normal and elevated IOP. The IOP reduction was stable throughout the 26 weeks. These data suggest that OMDI provides a novel efficacious treatment option for subjects with OAG or OHT with once-daily dosing.

Sponsored by Santen.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×